Shares of OS Therapies Incorporated (NYSEAMERICAN:OSTX - Get Free Report) fell 3.2% during trading on Monday. The stock traded as low as $1.20 and last traded at $1.21. 247,110 shares were traded during trading, a decline of 66% from the average daily volume of 717,797 shares. The stock had previously closed at $1.25.
Wall Street Analysts Forecast Growth
Separately, Roth Capital began coverage on OS Therapies in a report on Thursday, July 9th. They issued a "buy" rating and a $7.00 price objective on the stock. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, OS Therapies has an average rating of "Moderate Buy" and a consensus price target of $13.33.
Read Our Latest Research Report on OSTX
OS Therapies Stock Performance
The business has a 50-day moving average of $1.59 and a 200-day moving average of $1.57. The stock has a market capitalization of $55.82 million, a price-to-earnings ratio of -1.11 and a beta of -0.64.
OS Therapies (NYSEAMERICAN:OSTX - Get Free Report) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.20) earnings per share (EPS) for the quarter. Equities analysts predict that OS Therapies Incorporated will post -0.73 earnings per share for the current fiscal year.
Institutional Investors Weigh In On OS Therapies
A hedge fund recently bought a new stake in OS Therapies stock. Sanders Morris Harris LLC purchased a new stake in OS Therapies Incorporated (NYSEAMERICAN:OSTX - Free Report) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 20,000 shares of the company's stock, valued at approximately $32,000.
About OS Therapies
(
Get Free Report)
OS Therapies, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for osteosarcoma, a rare and aggressive bone cancer, as well as other solid tumors. The company's research centers on immunotherapy approaches intended to stimulate the immune system to recognize and attack cancer cells.
OS Therapies' lead product candidate is OST-HER2, an investigational HER2-targeted immunotherapy based on an attenuated form of Listeria monocytogenes. The candidate is being developed for patients with HER2-expressing cancers, including osteosarcoma, and may have potential applications in other solid tumors.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider OS Therapies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OS Therapies wasn't on the list.
While OS Therapies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.